Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

Q4 Medicine Revista Espanola de Patologia Pub Date : 2023-04-01 DOI:10.1016/j.patol.2023.02.002

Dolores Isla , María D. Lozano , Luis Paz-Ares , Clara Salas , Javier de Castro , Esther Conde , Enriqueta Felip , Javier Gómez-Román , Pilar Garrido , Ana Belén Enguita

{"title":"Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica","authors":"Dolores Isla , María D. Lozano , Luis Paz-Ares , Clara Salas , Javier de Castro , Esther Conde , Enriqueta Felip , Javier Gómez-Román , Pilar Garrido , Ana Belén Enguita","doi":"10.1016/j.patol.2023.02.002","DOIUrl":null,"url":null,"abstract":"<div>Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing (NGS) facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses.In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.</div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Patologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699885523000077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing (NGS) facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses.

In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

确定非小细胞肺癌预测生物标志物的建议的新更新：西班牙病理解剖学会和西班牙医学肿瘤学会的全国共识

非小细胞肺癌癌症（NSCLC）是确定的治疗靶点最多的，其中一些靶点具有治疗作用。目前，在这些患者中检测EGFR、BRAF、KRAS和MET突变、ALK、ROS1、NTRK和RET易位以及PD-L1表达被认为是至关重要的。下一代测序（NGS）的使用有助于精确的分子诊断，并允许检测其他新出现的突变，如HER2突变和免疫治疗反应的预测生物标志物。在这一共识中，由西班牙病理学学会（SEAP）和西班牙医学肿瘤学会（SEOM）选出的一组NSCLC诊断和治疗专家评估了目前可用的信息，并提出了一系列建议，以优化日常临床实践中生物标志物的检测和使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊